F
FRX
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, FRX has underperformed S&P TSX Composite Index (Canada), delivering a return of +19% compared to the S&P TSX Composite Index (Canada)'s +29% growth.
Stocks Performance
FRX vs S&P TSX Composite Index (Canada)
Performance Gap
FRX vs S&P TSX Composite Index (Canada)
Performance By Year
FRX vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Fennec Pharmaceuticals Inc
Glance View
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.
